Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19 (M2C2)
Status
Conditions
Treatments
Details and patient eligibility
About
To better understand the role of inflammation in COVID-19, we established the Michigan Medicine COVID-19 Cohort (M2C2). M2C2 is a funded and ongoing cohort which has currently enrolled over 1500 adult patients (≥18 years) with severe COVID-19 admitted at the University of Michigan. The purpose of M2C2 is to define the in-hospital course of these patients and understand the role of inflammation as a determinant of organ injury and outcomes in COVID-19.
Full description
The Michigan Medicine COVID-19 Cohort is a prospective observational cohort study of patients hospitalized specifically for COVID-19 at the University of Michigan Health System in Ann Arbor. Medical records of all consecutive patients with a positive SARS-CoV-2 are reviewed, and patients with confirmed SARS-CoV-2 infection but not primarily admitted for COVID-19 were excluded.
Biologic samples of patients enrolled in M2C2 were collected, and clinical characteristics including in-hospital outcomes were characterized in detail.
Biomarkers measured include, but not be limited to, soluble urokinase plasminogen activator receptor (suPAR), high sensitive C reactive protein (hs-CRP), brain natriuretic protein (BNP), high sensitive troponin T (hsTnT), interleukin 6 (IL-6), osteopontin, a2-antiplasmin.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Confirmed SARS-CoV-2 infection
- Hospitalized primarily for the treatment of COVID-19
Exclusion criteria
- SARS-CoV-2 positive but hospitalized for non-COVID-19 reasons
Trial design
3,402 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Penney Kunkle; Salim Hayek, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal